No near-term catalysts — the ongoing clinical holds on both lead programs extend uncertainty. Traders should watch for FDA engagement updates expected in Q2 2026, which could either restore some confidence or further pressure the stock.
Price Chart
Executive Summary
Aardvark Therapeutics reported Q1 2026 net loss of $21.6M ($0.99 per share), missing consensus of $(0.91) by 8.8%. Both ARD-101 and ARD-201 programs remain on voluntary clinical hold with no resolution yet, as cash burn accelerated and cash reserves fell to $91.2M. No new guidance was provided beyond a promise of further update in Q2 2026.
Key Financial Metrics
Key Facts
- Q1 2026 net loss: $21.6M vs $9.3M in Q1 2025
- EPS: $(0.99) vs consensus $(0.91) — miss of ~8.8%
- Cash & equivalents: $91.2M as of March 31, 2026 (down from $110.0M at Dec 31, 2025)
- Phase 3 HERO trial for ARD-101 remains on voluntary pause since Feb 2026; ARD-201 programs also paused
- Management expects to provide further program guidance in Q2 2026
Financial Impact
Net loss per share $-0.99 vs $-0.81 consensus (using Street consensus); cash burn ~$18.8M in the quarter
Risk Factors
- Potential for program termination or extended clinical hold
- Cash runway only into mid-2027; may require dilutive financing if trials do not resume
- No revenue stream to offset operating losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-210664 |
| Document: ck0001774857-20260507.htm | 0001193125-26-210664 |
| Document: 0001193125-26-210664-index-headers.html | 0001193125-26-210664 |
| Document: 0001193125-26-210664-index.html | 0001193125-26-210664 |
| Document: 0001193125-26-210664.txt | 0001193125-26-210664 |
| 8-K Data (Synthetic) | 0001193125-26-210664 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $3.00 | awaiting T+1 | — | $1.02 (−65.83%) |
Oct 22, 2026 3d ago | 8-K | $3.95 | awaiting T+1 | — | $1.02 (−74.05%) |
Oct 22, 2026 3d ago | Press Release | $3.95 | awaiting T+1 | — | $1.02 (−74.05%) |
Oct 8, 2026 17d ago | 3 | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.02 (−78.47%) |
Oct 8, 2026 17d ago | 8-K | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.02 (−78.47%) |
Aug 12, 2026 10w ago | Institutional Cluster | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.02 (+84.40%) |
Aug 11, 2026 10w ago | 8-K | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.02 (+84.40%) |
Aug 11, 2026 10w ago | Press Release | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.02 (+84.40%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.64 $3.90 | ▲ +7.14% | ▲ +6.60% | $1.02 (−71.84%) |
May 14, 2026 23w ago | Press Release | $4.57 $4.36 | ▲ +4.60% | ▲ +4.53% | $1.02 (+77.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers